Leishmania donovani
ZOOA-DSE(A)-5-1 UNIT-2
Aditi Ghosh
Systematic Position(Levine et al,1980)
Kingdom : Protista
Subkingdom : Protozoa
Phylum : Sarcomastigophora
Subphylum : Mastigophora
Class: Zoomastigophora
Order: Kinetoplastida
Genus : Leishmania
Species : L.donovani
PREVALENCE
Endemic in many places in India, China, Africa, Southern Europe, South America and Russia.
In India, it is specaily common in Assam and Bengal along the coasts of the Ganges and the Brahmaputra. It is also endemic in Bihar, Orissa, Madras and the eastern parts of Uttar Pradesh as far as Lucknow.
HABITAT : Inside the vertebrate host (man) the parasite is always intra-cellular, occurring in the amastigote form. It is essentially a parasite of the R.E. system.
EPIDEMIOLOGY
The disease caused by infection with Leishmania donovani is called Kala azar Or black fever. It is an extremely rare disease with fewer than 5thousand cases per year (India). Visceral Leishmaniasis is spread by sandfly bites. This type of Leishmaniasis affects the internal organs ; usually the spleen, liver, etc. Some of the common symptoms include - (a) Pain in the abdomen(b) Fever, loss of appetite,
anemia, night sweats(c) Diarrhea(d) Abnormally thin and
greyish discoloration of the skin (e) swollen lymph nodes etc
PKDL develops in about 10℅ of kala azar patients generally
one or two years after completion of antimonial treatment for
the original disease where the visceral infection disappears but
the skin infection persists. It is prevalent in endemic areas of
kala azar in India chiefly in Bengal less so in Madras and Assam.
In India, man is the main or only source of infection acting as a
reservoir of the disease.
MORPHOLOGY
The parasite exists in two forms :
The characteristics of the amastigote form are as follows –
the anterior end.
projecting from the front. The flagellum does not curve round
the body of the parasite.
LIFE CYCLE OF L.donovani
PATHOGENECITY
Incubation Period- This is the period when the time of the initial infection and the appearance of clinical manifestation takes place . It generally varies from three to six months but it may exceed one and sometimes two years.
Infection with L. Donovani produces the disease Kala Azar or Visceral Leishmaniasis characterized by the following clinical features-
(a)Pyrexia is often an early symptom. In 20 percent of the cases, pyrexia shows a double rise in 24hours.
(b)Splenomegaly - Splenic enlargement is one of the most striking features but the rate of splenic enlargement may vary from patient to patient.
(c) Liver is also enlarged but not as much as the spleen.
(d) Anemia becomes noticeable.
(e) The skin over the entire body is dry rough and harsh and is often pigmented (darkened).
(f) Hair tends to be brittle and falls out.
(g) If left untreated, 70℅ to 90℅ of the patients die within a period of 2 years. Death in kala-azar is always due to some complications, such as amoebic or bacillary dysentry , pneumonia, pulmonary tuberculosis and other septic infections.
SPECIAL CLINICAL FEATURES
Mediterranean area, Latin America . In India, the peak age is
5-9 years or older. The common symptoms are fever, malaise,
weight loss, anorexia accompanied by enlargement of the spleen,
anemia and skin darkening.
entering a epidemic area. It is characterized
by a markedly sudden onset of fever, 3weeks to 2 years after exposure.
those who are old enough.
DIAGNOSIS
DIRECT EVIDENCES | INDIRECT EVIDENCES |
|
|
| |
PROPHYLAXIS
The preventive measures include the following :
1.Attack on the Parasite : In India, control measures should be treatment campaign, whereas in China and Mediterranean areas the campaign areas should be directed against dogs serving as reservoirs of infection.
2.Attack on the Vector : This consists of measures directed against the sandfly, the transmitting agent. This can be achieved by clearing out low trees and bushes etc in endemic areas.
3. Personal Prophylaxis : Use of mosquito-net or screen(of 22 meshes to the square inch)avoiding the ground floor for sleeping purposes and periodic fumigation of sleeping quarters.
TREATMENT
The specific chemotherapeutic drugs include the following :
1.Antimony compounds : Pentavalent Antimony compound is now the drug of choice and includes sodium-antimony-gluconate(SAG 600mg daily for 6-10 days)
2.Synthetic non-metallic compound: Pentamidine isethionate (4mg/kg/day IM for 10 days)
THANK YOU
� ��